Dutch FF Pharma has a Promising Immunotherapy to fight Crohn’s Disease

05/08/2016 - 2 minutes

Arrivederci Italia! We’re going to fly up to the Netherlands for another Biotech-related adventure! This time, we’re visiting Utrecht, the fourth most populated city in the country and home-base to FF Pharma, our Biotech of the Week!

ff pharma logo

City: Utrecht (The Netherlands)

Founded: 2012

Employees: N/A

Financial Data: €4M Total Raised (as of 12/2015)

CEO: Mark De Boer

mark de boer ceo ffpharma

Mission: FF Pharma focuses on the immune system, developing an antibody that targets CD40 – a major regulatory receptor. CD40 seems to play a big role in a variety of autoimmune diseases.

Its candidate is FFP104, currently in clinical development. The therapy is in a Phase I/II trial for Primary Biliary Cirrhosis (PBC), a rare disease where small bile ducts in the liver to become inflamed. Results from this study are expected soon, in the second half of 2016.

FFP104 is also in a second study,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member